Yury Kustov | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist Awards

Best Researcher Award

Yury Kustov
Peoples’ Friendship University of Russia
Yury Kustov
Affiliation Peoples’ Friendship University of Russia
Country Russia
Scopus ID 58987836800
Documents 5
Citations 4
h-index 1
Subject Area Medicine and Health Sciences
Event International Forensic Scientist Awards
ORCID 0009-0002-4859-4322

Yury Kustov is a researcher affiliated with the Peoples’ Friendship University of Russia whose scholarly work focuses on medicine, pharmacovigilance, drug safety, pulmonary fibrosis, and clinical pharmacology. His recent publications examine adverse drug reactions, pediatric pharmacotherapy, pulmonary complications, and systematic reviews related to pharmacokinetics and post-COVID-19 outcomes. Through contributions indexed in Scopus, Kustov has participated in interdisciplinary investigations concerning patient safety and evidence-based medical analysis.[1] His profile reflects active engagement in healthcare-related research areas associated with pharmacological monitoring and clinical risk assessment.[2]

Abstract

The academic contributions of Yury Kustov are associated with contemporary clinical medicine and pharmacovigilance research. His published studies explore adverse drug reactions, pulmonary fibrosis, antibiotic safety, and pediatric therapeutic outcomes. Several investigations emphasize spontaneous report database analysis and systematic reviews in order to improve healthcare monitoring and pharmacological safety standards.[3] These contributions support broader scientific discussions regarding medication-related complications and patient-centered clinical evaluation.

Keywords

Pharmacovigilance, Clinical Pharmacology, Pulmonary Fibrosis, Pediatric Medicine, Drug Safety, Post-COVID Research, Pharmacokinetics, Medicine and Health Sciences.

Introduction

The advancement of modern healthcare increasingly depends on pharmacological safety assessment and evidence-based therapeutic monitoring. Researchers involved in pharmacovigilance contribute to the identification of adverse reactions and clinical complications linked to pharmaceutical interventions. Yury Kustov has participated in this research landscape through studies addressing antibacterial drug reactions, pulmonary fibrosis, and pediatric medicine.[4] His publications demonstrate engagement with healthcare datasets and clinical literature reviews that contribute to scientific understanding of treatment-related risks.

Research Profile

Kustov’s academic profile includes journal articles and conference publications indexed through Scopus and related scholarly databases. His research areas include pharmacokinetics in chronic heart failure, pulmonary fibrosis associated with pharmacotherapy, and pediatric antibacterial drug safety. The researcher has also examined Stevens–Johnson syndrome and toxic epidermal necrolysis using spontaneous reporting systems.[5] These studies align with medical efforts to improve treatment evaluation and patient safety methodologies.

Research Contributions

  • Analysis of fluoroquinolone safety in pediatric populations through pharmacovigilance database studies.
  • Systematic review research concerning pharmacokinetic alterations in chronic heart failure patients.
  • Investigations into pulmonary fibrosis and post-COVID-19 pharmacotherapy outcomes.
  • Evaluation of spontaneous adverse drug reaction reports linked to antibacterial medications.

Publications

  • “Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis”
  • “Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review”
  • “Drug-Induced Pulmonary Fibrosis: National Database Analysis”

Research Impact

The research contributions of Yury Kustov demonstrate relevance to healthcare monitoring, medication safety assessment, and evidence-based pharmacology. By utilizing systematic reviews and spontaneous report analyses, his studies contribute to discussions surrounding adverse drug reaction surveillance and therapeutic evaluation. Such research supports clinicians, pharmacologists, and healthcare researchers seeking to understand treatment-related complications in vulnerable patient populations.

Award Suitability

Yury Kustov’s publication record and involvement in pharmacovigilance-related medical studies align with the objectives of the International Forensic Scientist Awards. His focus on drug safety analysis, pulmonary complications, and healthcare risk assessment reflects scholarly engagement with medically significant challenges. The integration of database-driven clinical analysis and systematic review methodologies further demonstrates research activity associated with modern healthcare science and patient protection initiatives.

Conclusion

Yury Kustov has contributed to medicine and health sciences through publications examining pharmacovigilance, pulmonary fibrosis, clinical pharmacology, and pediatric drug safety. His academic profile reflects ongoing participation in evidence-based medical research and healthcare monitoring studies. Through indexed scholarly outputs and DOI-linked publications, his work contributes to the broader scientific understanding of pharmaceutical safety and patient-centered clinical investigation.

References

  1. Elsevier. (n.d.). Scopus author details: Yury Kustov, Author ID 58987836800. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=58987836800
  2. ORCID. (n.d.). Yury Kustov ORCID profile.
    https://orcid.org/0009-0002-4859-4322
  3. Kustov, Y. (2026). Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis.
    https://doi.org/10.1177/09246479251398995
  4. Kustov, Y. (2025). Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review.
    https://doi.org/10.3390/ijms26199495
  5. Kustov, Y. (2024). Drug-Induced Pulmonary Fibrosis: National Database Analysis.
    https://doi.org/10.3390/biomedicines12122650

Hong Zhang | Medicine and Health Sciences | Innovative Research Award

Published on by Forensic Scientist Awards

Innovative Research Award

Hong Zhang
University of Texas Southwestern Medical Center, United States
Hong Zhang
Affiliation University of Texas Southwestern Medical Center
Country United States
Scopus ID 57192482890
Documents 28
Citations 550
h-index 13
Subject Area Medicine and Health Sciences
Event International Forensic Scientist Awards
ORCID 0000-0003-3056-0343

Hong Zhang, is an orthopedic surgeon, biomedical innovator, and musculoskeletal research specialist affiliated with the University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital for Children in Dallas, Texas. His research activities focus primarily on pediatric spinal deformities, growth modulation, spinal instrumentation development, scoliosis correction technologies, and minimally invasive spinal surgery. Through a combination of clinical orthopedic expertise and translational biomedical engineering, Zhang has contributed to the development of novel surgical systems and patented technologies intended to improve the treatment of severe spinal deformities and early-onset scoliosis.[1]

As Director of the Division of Creative Innovations within the Seay Center for Musculoskeletal Research, Zhang has overseen multidisciplinary investigations involving experimental spine biomechanics, orthopedic implant design, pediatric spine growth modulation, and surgical correction strategies. His publication record, citation metrics, and patent portfolio demonstrate sustained scholarly engagement in orthopedic research and spinal deformity innovation.[2]

Abstract

Hong Zhang is recognized for contributions to orthopedic surgery research, spinal deformity correction technologies, and pediatric musculoskeletal innovation. His work has focused on improving surgical outcomes for severe scoliosis and kyphosis through biomechanical research, implant design, and translational clinical investigations. Zhang has also contributed to orthopedic device development through multiple United States patents related to spinal correction systems and stabilization technologies.[3] His scholarly publications in journals such as Spine Deformity, European Spine Journal, and Seminars in Spine Surgery highlight continued engagement in experimental spine research and orthopedic innovation.[4]

Keywords

Orthopedic Surgery, Pediatric Scoliosis, Spinal Deformity, Spine Research, Musculoskeletal Innovation, Early-Onset Scoliosis, Orthopedic Instrumentation, Growth Modulation, Biomedical Engineering, Pediatric Orthopedics

Introduction

The field of pediatric spinal deformity research requires coordinated advances in biomechanics, surgical techniques, implant engineering, and long-term clinical evaluation. Hong Zhang has contributed to this interdisciplinary area through research addressing early-onset scoliosis, thoracic deformities, vertebral correction systems, and growth-preserving spinal interventions. His investigations combine experimental orthopedic science with clinically applicable instrumentation design.[5]

Zhang obtained his medical degree from Tianjin Medical University in China and completed orthopedic surgery training at Tianjin Hospital before undertaking international orthopedic research and clinical scholarship programs in Italy and the United States. Since joining the University of Texas Southwestern Medical Center and Texas Scottish Rite Hospital for Children, he has participated in numerous collaborative orthopedic research initiatives focused on pediatric spine disorders and surgical innovation.[6]

Research Profile

Hong Zhang currently serves as Director of the Division of Creative Innovations within the Center of Excellence in Spine Research at the Seay Center for Musculoskeletal Research, Texas Scottish Rite Hospital for Children, Dallas, Texas. He also holds the academic position of Associate Professor in the Department of Orthopaedic Surgery at the University of Texas Southwestern Medical Center.[1]

His research profile demonstrates sustained focus on pediatric spinal deformities, including early-onset scoliosis, thoracic kyphosis, spinal growth modulation systems, minimally invasive thoracoscopic procedures, and spinal instrumentation biomechanics. Zhang’s work frequently integrates engineering methodologies, experimental spine models, and translational orthopedic device development.[7]

  • Early-onset scoliosis and pediatric spine growth research
  • Orthopedic implant and spinal instrumentation development
  • Growth modulation systems for spinal correction
  • Biomechanical evaluation of spinal deformity devices
  • Experimental and translational musculoskeletal research
  • Minimally invasive spinal surgical technologies

Research Contributions

Zhang has contributed extensively to the development of innovative spinal correction systems intended for severe spinal deformities and pediatric scoliosis treatment. His patented orthopedic technologies include spinal rod reduction devices, pedicle screw systems, stabilization fasteners, and hinge-link spinal correction devices designed to improve alignment control and surgical correction efficiency.[8]

A significant component of his recent research involves the development of growth modulation systems using dynamic spinal correction approaches. Experimental investigations involving porcine models and three-dimensional simulation technologies have supported the evaluation of biomechanical effectiveness and safety profiles of novel correction systems.[9]

Zhang’s work on vertebral column resection systems and angular kyphosis reduction devices has also contributed to understanding correction strategies for severe thoracic spinal deformities. These studies have explored both implant mechanics and surgical feasibility in complex deformity correction procedures.[10]

  • Development of hinge-link spinal correction technologies
  • Novel uniplanar correction systems for angular kyphosis
  • Dynamic scoliosis correction and growth modulation research
  • Biomechanical studies of pediatric spinal instrumentation
  • Experimental orthopedic implant design and testing

Publications

Hong Zhang has authored and co-authored multiple peer-reviewed scientific publications addressing pediatric scoliosis, thoracic deformity correction, spine biomechanics, and orthopedic surgical technologies.[11]

  1. Zhang H, Lima JM, Jo CH, and Sucato DJ. The closing triradiate cartilage stage identifies accelerated curve progression in idiopathic scoliosis. Spine Deformity (2026).
  2. Zhang H, Ross D, and Sucato DJ. Evaluation of a novel angular kyphosis reduction device for vertebral column resection in severe angular kyphosis. European Journal of Orthopaedic Surgery & Traumatology (2026).
  3. Zhang H, Ross D, and Sucato DJ. A new uniplanar correction strategy for severe thoracic kyphosis: concept, device design, and simulation with a 3D-printed model. Spine Deformity (2026).
  4. Zhang H, Niese B, and Sucato DJ. Growth modulation and dynamic correction of early-onset thoracic scoliosis using a PEEK spring rib plate system: a porcine model study. Spine Deformity (2026).
  5. Brooks JT, Carron CJ, Zhang H, and Sucato DJ. Going anterior for the surgical management of pediatric scoliosis: Indications and technique pearls. Seminars in Spine Surgery (2025).

Research Impact

According to available Scopus metrics, Zhang has produced 28 indexed scholarly documents with approximately 550 citations and an h-index of 13, reflecting measurable academic influence within orthopedic surgery and musculoskeletal research communities.[1] His research output has contributed to the scientific understanding of pediatric spinal deformities, spinal growth dynamics, and orthopedic implant biomechanics.

His work has also received recognition through national and international awards, including the John H. Moe Award for Best Basic Science presented by the Scoliosis Research Society in both 2009 and 2010.[12] Additional grant support from organizations such as the Pediatric Orthopedic Society of North America and the Scoliosis Research Society further reflects the relevance of his investigations within pediatric orthopedic research.

Award Suitability

Hong Zhang’s academic profile aligns with the objectives of the Innovative Research Award due to his sustained contributions to orthopedic surgery innovation, spinal deformity correction technologies, and translational pediatric spine research. His work demonstrates interdisciplinary integration between clinical orthopedic practice, biomechanical engineering, and experimental medical device development.[8]

The combination of peer-reviewed publications, patented surgical systems, funded research projects, and international scientific recognition supports consideration of Zhang’s contributions within the field of medicine and health sciences. His focus on improving treatment strategies for complex pediatric spinal conditions reflects ongoing commitment to clinically relevant biomedical innovation.[10]

Conclusion

Hong Zhang has established a scholarly and clinical research profile centered on pediatric orthopedic innovation and spinal deformity correction. Through collaborative orthopedic research, patented instrumentation systems, and translational experimental studies, he has contributed to the advancement of spinal surgery technologies and pediatric musculoskeletal care. His publication history, research awards, and scientific contributions collectively support recognition within international academic and biomedical innovation platforms.[11]

References

  1. Elsevier. (n.d.). Scopus author details: Hong Zhang, Author ID 57192482890. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57192482890
  2. University of Texas Southwestern Medical Center. (n.d.). Faculty and research profile information for Hong Zhang.
  3. United States Patent and Trademark Office. (2010). Method for the Correction of Spinal Deformities Using Rod-Plate Anterior System.
  4. Springer Nature. (2026). Spine Deformity journal publications authored by Hong Zhang.
  5. Zhang H, Ross D, and Sucato DJ. (2026). Evaluation of a novel angular kyphosis reduction device for vertebral column resection in severe angular kyphosis.
    https://doi.org/10.1007/s00590-026-04778-y
  6. Texas Scottish Rite Hospital for Children. (n.d.). Seay Center for Musculoskeletal Research profile.
  7. Zhang H, Niese B, and Sucato DJ. (2026). Growth modulation and dynamic correction of early-onset thoracic scoliosis using a PEEK spring rib plate system.
    https://doi.org/10.1007/s43390-026-01284-3
  8. United States Patent and Trademark Office. (2023). Hinge-Link Spinal Correction Device and Method.
  9. Wang XB, Zhang H, and Sucato DJ. (2023). Unilateral thoracic spinal nerve resection creates early onset thoracic scoliosis in an immature porcine model.
    https://doi.org/10.1007/s00586-023-07804-3
  10. Zhang H, Ross D, and Sucato DJ. (2024). A Novel Uniplanar Clamp-Hinge Correction System for Vertebral Column Resection of Severe Angular Kyphosis.
    https://doi.org/10.1007/s43390-023-00770-2
  11. Elsevier. (n.d.). Publication and citation metrics for Hong Zhang in orthopedic research.
  12. Scoliosis Research Society. (2010). John H. Moe Award for Best Basic Science.

Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist Awards

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Published on by Forensic Scientist Awards

Mr. Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Institute of Legal Medicine and Forensic Sciences of Valencia | Spain

Mr. Alfonso Colorado Casado de Amezúa is a highly respected forensic physician whose career demonstrates a profound commitment to advancing forensic science, medico-legal education, and public communication of specialized knowledge. Currently serving as Director of the Institute of Legal Medicine and Forensic Sciences of Valencia, he has built a distinguished professional record over more than fifteen years, holding key roles across Spain in Catalonia, Albacete, Cuenca, Guadalajara, and Valencia. His leadership has been pivotal in forensic pathology and disaster victim identification, where he has developed and applied protocols for managing mass casualty events with precision and compassion. Alongside his clinical and administrative responsibilities, Mr. Alfonso Colorado Casado de Amezúa has played a central role in training the next generation of forensic professionals. As adjunct professor at the University CEU-Cardenal Herrera in Valencia and Castellón, and as lecturer in numerous specialized courses for forensic doctors, law enforcement, and emergency response teams, he has demonstrated an exceptional ability to communicate complex forensic concepts with clarity and authority. His scientific contributions, including publications in the Revista Española de Medicina Legal and CorSalud, have provided valuable insights into sudden cardiac death and forensic practices in disaster contexts, strengthening both research and applied forensic work. As organizer and speaker in national training programs, he has further enhanced the visibility of forensic medicine and ensured the dissemination of best practices across Spain. By uniting research, practice, and communication, Mr. Colorado embodies the mission of forensic science to serve justice and society, making him an outstanding nominee for the Forensic Science Communication Award.

Profile: ORCID

Featured Publications

Colorado Casado de Amezúa, A., Garrido-Lestache López-Belmonte, E., & Giner Blasco, J. (2025). Medical forensic response during the flood in Valencia (Spain), October 29th, 2024 [Actuación médico-forense durante la riada en Valencia (España) el 29 de octubre de 2024]. Revista Española de Medicina Legal. Advance online publication.

Colorado, A., & Fernández Bayón, J. (2009). Síndrome de Loeys-Dietz. Diagnóstico diferencial en muerte súbita por disección aórtica. Revista Española de Medicina Legal, 35(2), 67–71.

Long Chang | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist Awards

Dr. Long Chang | Medicine and Health Sciences | Best Researcher Award

Peking Union Medical College Hospital | China

Dr. Long Chang is an accomplished physician and clinical researcher whose career demonstrates excellence in patient care and significant contributions to hematology. He currently serves as an Attending Physician at the Department of Hematology, Peking Union Medical College Hospital, Beijing, China, building upon his medical training at Peking Union Medical College, Tsinghua University. His research focuses on rare hematologic disorders, particularly myeloproliferative neoplasms and histiocytic diseases, with emphasis on improving diagnostic precision, expanding therapeutic strategies, and enhancing patient outcomes. According to Scopus (Author ID: 57225110413), Dr. Long Chang has authored 39 publications, which have collectively received 165 citations across 152 documents, reflecting the impact of his work, and holds an h-index of 6. He has published influential studies in leading journals including Leukemia, EClinicalMedicine, Oncologist, and Orphanet Journal of Rare Diseases. His work has advanced treatment options for Rosai-Dorfman disease and Langerhans cell histiocytosis while also providing novel insights into gamma heavy chain disease. Notably, his clinical trials have introduced promising approaches such as low-dose cytarabine and novel immunomodulatory therapies, offering alternatives for conditions with limited treatments. Beyond publications, Dr. Long Chang demonstrates commitment to translational medicine by bridging molecular research with patient-centered care. Recognized by peers for his rigor, innovation, and leadership, he has progressed from Resident and Chief Resident to Attending Physician, reflecting both clinical expertise and academic excellence. With impactful contributions influencing practice worldwide, Dr. Long Chang exemplifies the qualities of a dedicated physician-scientist whose work continues to advance the frontiers of hematology.

Profile: Scopus

Featured Publications

  • Chang, L., Zhou, D. B., & Cao, X. X. (2023). Gamma heavy chain disease: A retrospective analysis of 6 cases. Orphanet Journal of Rare Diseases, 18(1), 77.

  • Chang, L., Qiao, B., Cai, H., et al. (2023). Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease. Leukemia, 37(11), 2297–2300.

  • Chang, L., Lang, M., Lin, H., et al. (2024). Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia, 38(4), 803–809.

  • Chang, L., Lang, M., Liu, T., et al. (2024). Lenalidomide and dexamethasone for Rosai-Dorfman disease: A single arm, single center, prospective phase 2 study. EClinicalMedicine, 73, 102685.

  • Chang, L., Cai, H. C., Lang, M., et al. (2024). Liver involvement with Langerhans cell histiocytosis in adults. The Oncologist. Advance online publication.

Yan Bai | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist Awards

Dr. Yan Bai | Medicine and Health Sciences | Best Researcher Award

Yunnan University | China

Dr. Yan Bai is a highly accomplished postdoctoral researcher at the State Key Laboratory of Conservation and Utilization of Bio-resources in Yunnan and the Center for Life Sciences, School of Life Sciences, Yunnan University, Kunming, China. She earned her PhD in Cell Biology from Yunnan University, MSc in Pharmacology from the Chinese PLA Medical Academy, and BSc in Pharmacy from Dali University, establishing a strong interdisciplinary foundation spanning pharmacology, microbiology, and cellular biology. Prior to her current role, she conducted research at the Chinese PLA General Hospital, focusing on combination therapies against multidrug-resistant bacteria. Her research primarily investigates mitochondrial homeostasis, tumor biology, and the molecular mechanisms underlying mitochondrial genetic diseases, with particular attention to mitochondria-associated condensates (MATOs) as regulators of protein translation and mitochondrial integrity. Dr. Yan Bai has led and contributed to several major research projects, including grants from the National Natural Science Foundation of China, the National Basic Research Program, and Yunnan Province Science and Technology initiatives. Her work has resulted in high-impact publications in journals such as Nature Aging (2025), Sci China Life Sci (2025), EMBO J (2024), and Biophys Rep (2024). According to Scopus, she has authored 10 publications, cited 177 times across 169 documents, with an h-index of 6, demonstrating both productivity and influence in her field. Through her interdisciplinary collaborations, innovative experimental approaches, and groundbreaking findings on mitochondrial regulation and aging, Dr. Yan Bai has made significant contributions to biomedical science, advancing understanding of mitochondrial biology, disease mechanisms, and translational biomedical applications.

Profile: Scopus

Featured Publications

Bai, Y., Ma, T., Zhao, S., Li, S., Wang, X., Li, J., Sun, W., Yang, Y., Liu, F., Shan, Q., Qin, Z., Liu, N., Zhang, J., Tian, F., Duan, M., Chen, S., Lai, F., Chen, Q., Wu, X., & Yang, C. (2025). Mitochondria-associated condensates maintain mitochondrial homeostasis and promote lifespan. Nature Aging.

Hao, Q., Bai, Y., Guan, R., Dong, R., Bai, W., Hamdy, H., Wang, L., Meng, M., Sun, Y., Shen, J., & Sun, J. (2025). VPS35/Retromer-dependent MT1-MMP regulation confers melanoma metastasis. Science China Life Sciences, 68(7), 1996–2009.

Hao, Q., Dong, R., Bai, W., Chang, D., Yao, X., Zhang, Y., Xu, H., Li, H., Kui, X., Wang, F., Wang, Y., Wang, C., Lei, Y., Chen, Y., Shen, J., Sang, L., Bai, Y., & Sun, J. (2024). Screening for metastasis-related genes in mouse melanoma cells through sequential tail vein injection. Biophysical Reports, 10(1), 15–21.

Liu, F., Li, T., Gong, H., Tian, F., Bai, Y., Wang, H., Yang, C., Li, Y., Guo, F., Liu, S., & Chen, Q. (2024). Structural insights into the molecular effects of the anthelmintics monepantel and betaine on the Caenorhabditis elegans acetylcholine receptor ACR-23. EMBO Journal, 43(17), 3787–3806.

Wang, T., Zhou, X., Bai, Y., Zhang, L., Li, L., & Wu, C. (2018). Antiepileptic effect of uridine may be caused by regulating dopamine release and receptor expression in corpus striatum. Brain Research, 1688, 47–53.

Bai, Y., Liu, B., Wang, T., Cai, Y., Liang, B., Wang, R., Liu, Y., & Wang, J. (2015). In vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 59(3), 1466–1471.

Liu, B., Bai, Y., Liu, Y., Di, X., Zhang, X., Wang, R., & Wang, J. (2015). In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii. Journal of Chemotherapy, 27(5), 271–276.

Begum Ertan | Medicine and Health Sciences | Young Researcher Award

Published on by Forensic Scientist Awards

Dr. Begum Ertan | Medicine and Health Sciences | Young Researcher Award

Sandikli State Hospital | Turkey

Dr. Begum Ertan is an accomplished medical doctor and specialist in Gynecology and Obstetrics, serving at Afyonkarahisar Sandikli State Hospital. She is recognized for her dedication to advancing women’s reproductive health, blending clinical expertise with a strong commitment to academic research. Her work spans adenomyosis diagnosis, infertility treatment, IVF success prediction, and gynecologic oncology. Actively engaged in professional societies, she is a core group member of the Turkish Endometriosis and Adenomyosis Society. Dr. Ertan combines patient-centered care with cutting-edge scientific approaches, striving to improve diagnostic accuracy, treatment outcomes, and overall quality of life for women.

Professional Profile

Scopus

Education

Dr. Ertan completed her medical degree at Celal Bayar University, Faculty of Medicine, where she laid a strong foundation in clinical sciences and patient care. She then specialized in Obstetrics and Gynecology at Dokuz Eylül University, Faculty of Medicine, developing advanced skills in reproductive medicine, maternal-fetal health, and minimally invasive surgical techniques. Her education was enriched by exposure to diverse clinical cases and participation in academic projects, fostering her dual role as a skilled clinician and committed researcher.

Experience

With extensive experience as a Gynecology and Obstetrics Specialist, Dr. Ertan has managed complex cases involving high-risk pregnancies, reproductive endocrinology, and gynecologic surgery. She has contributed to multidisciplinary medical teams, enhancing patient outcomes through evidence-based approaches. Her professional activities include presenting original research at leading national and international conferences, authoring peer-reviewed publications, and writing academic book chapters on endometriosis, infertility, and hormonal therapies. In addition to her hospital duties, she actively participates in community health initiatives, delivering educational seminars on women’s health and hygiene.

Research Interests

Dr. Ertan’s research is driven by a commitment to improving women’s reproductive health through innovative diagnostic and therapeutic methods. She is particularly interested in adenomyosis detection using advanced imaging modalities, identifying predictive factors for IVF success, evaluating the impact of early pregnancy findings on pregnancy outcomes, and exploring rare gynecologic pathologies. Her studies also address the role of hysteroscopic evaluation in abnormal uterine bleeding and the relationship between ovarian conditions and fertility potential. By integrating clinical insight with research innovation, she aims to bridge the gap between academic findings and real-world patient care.

Awards

Dr. Ertan’s professional trajectory reflects the qualities sought in the Young Researcher Award  innovation, dedication, and measurable contributions to the field. Her growing portfolio of scientific publications, her active participation in professional societies, and her involvement in public health education underscore her status as a promising and impactful early-career researcher in obstetrics and gynecology.

Publications

  • Title: Prediction of adenomyosis according to revised definitions of morphological uterus sonographic assessment features
    Journal: Frontiers in Medicine
    Published on: August 2024

  • Title: Comparison of Patients with Adenomyosis Detected in Hysterectomy Material and Patients with Other Benign Pathologies: Retrospective Study
    Journal: Turkish Journal of Reproductive Medicine and Surgery
    Published on: 2024

  • Title: Impact of ovarian cysts observed on the initial day of ovulation induction on the success rates in IVF cycles
    Journal: Reproductive Bio Medicine Online
    Published on: November 2023

  • Title: Correlation of adenomyosis risk factors with pathologic diagnosis
    Journal: Reproductive Bio Medicine Online
    Published on: November 2023

  • Title: Pregnancy Loss Prediction Based on Early First Trimester Ultrasound
    Journal: Reproductive Bio Medicine Online
    Published on: November 2023

  • Title: Ovarian hilus cell hyperplasia and sertoli-leydig cell tumor in a patient with postmenopausal virilization: a rare case report
    Journal: Aegean Journal of Obstetrics and Gynecology
    Published on: December 2021

Conclusion

Dr. Begum Ertan embodies the profile of an emerging leader in reproductive medicine. Her clinical expertise, research productivity, and academic contributions have already made a significant impact on the field. Through her continued work in advanced gynecologic diagnostics, fertility treatment, and women’s health advocacy, she demonstrates exceptional promise as a young researcher. Her commitment to bridging scientific innovation with practical healthcare solutions makes her a strong and deserving candidate for the Young Researcher Award.

Qianghua Lv | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Prof. Dr. Qianghua Lv | Medicine | Best Researcher Award

Shandong Academy of Agricultural Sciences | China

Dr. Qianghua LV is an Associate Researcher at the Institute of Animal Science and Veterinary Medicine (IASVM), Shandong Academy of Agricultural Sciences (SAAS). He earned his Ph.D. in Veterinary Pharmacology under the mentorship of Prof. DENG Xuming at Jilin University in 2020. His research focuses on developing novel therapeutic strategies targeting bacterial virulence factors, including bacterial hemolysin, Type III Secretion System (T3SS), and Type IV Pili (TFP). His work contributes significantly to understanding anti-infective mechanisms and advancing new drug development against bacterial infections.

Profile👤

ORCID

Strengths for the Awards✨

  • High-Impact Research Focus – Dr. LV Qianghua’s work on anti-infection mechanisms and natural compound-based drug development aligns with global health priorities, particularly in combating superbacterial infections. His research on bacterial virulence factors like hemolysin, T3SS, and TFP contributes to the development of novel antimicrobial strategies.

  • Quality Publications in Reputable Journals – He has multiple first-author and co-first-author publications in high-impact journals, such as Journal of Cellular and Molecular Medicine and Applied Microbiology and Biotechnology. These papers focus on novel antibacterial mechanisms and natural product inhibitors, demonstrating both innovation and scientific rigor.

  • Translational Impact – His research not only advances basic microbiology but also holds significant translational potential in developing new antibacterial therapies, an area of urgent medical need due to rising antibiotic resistance.

  • Collaborative and Multi-Disciplinary Approach – His collaborations with researchers across multiple disciplines (pharmacology, microbiology, and veterinary medicine) enhance the applicability of his findings beyond veterinary science, benefiting both animal and human health.

  • Contribution to Veterinary Medicine – As an Associate Researcher at the IASVM, SAAS, Dr. LV contributes significantly to veterinary pharmacology, a field essential for both agricultural and public health. His work has implications for livestock disease management and food safety, making it highly relevant for both academia and industry.

🎓 Education

  • Ph.D. in Veterinary Pharmacology, Jilin University, 2020
    • Advisor: Prof. DENG Xuming
    • Research Focus: Anti-infection mechanisms of natural compounds targeting bacterial virulence factors

💼 Experience

  • Associate Researcher, IASVM, SAAS (2020–Present)
    • Conducting research on antibacterial strategies targeting virulence factors
    • Screening natural compounds for inhibitory effects on bacterial infections
    • Developing new therapeutic agents against superbacterial infections

🔬 Research Interests On Medicine

  • 🦠 Discovery and screening of novel targets and lead compounds against superb acterial infections
  • 💊 Synergistic antibacterial effects and mechanisms of natural compounds and antimicrobial agents

📚 Selected Publications

  • Title: Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium
    Authors: Lv Q(#), Chu X(#), Yao X, Ma K, Zhang Y*, Deng X*
    Publication Year: 2019
    Journal: Journal of Cellular and Molecular Medicine

  • Title: Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system
    Authors: Lv Q(#), Li S(#), Wei H, Wen Z, Wang Y, Tang T, Wang J, Xia L*, Deng X*
    Publication Year: 2020
    Journal: Applied Microbiology and Biotechnology

  • Title: Phloretin potentiates polymyxin E activity against Gram-negative bacteria
    Authors: Du R(#), Lv Q(#), Hu W, Hou X, Zhou Y, Deng X, Sun L, Li L, Deng Y, Wang J
    Publication Year: 2021
    Journal: Life Sciences

  • Title: Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection
    Authors: Zhou Y, Liu B, Chu X, Su J, Xu L, Li L, Deng X, Li D*, Lv Q*, Wang J*
    Publication Year: 2022
    Journal: Communications Biology

  • Title: Isoflavone glucoside genistin, an inhibitor targeting Sortase A and Listeriolysin O, attenuates the virulence of Listeria monocytogenes in vivo and in vitro
    Authors: Liu M(#), Lv Q(#), Xu J, Liu B, Zhou Y, Zhang S, Shen X, Wang L
    Publication Year: 2023
    Journal: Biochemical Pharmacology

🔚 Conclusion

Dr. LV Qianghua has dedicated his research to developing innovative antibacterial strategies, focusing on targeting bacterial virulence factors. His contributions in natural compound screening and new drug development have advanced the fight against superbacterial infections. With numerous impactful publications and ongoing research, he continues to make significant strides in veterinary medicine and pharmacology.

Yang Xu | Medicine | Best Researcher Award

Published on by Forensic Scientist Awards

Dr. Yang Xu | Medicine | Best Researcher Award

Associate chief physician | Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital | China

Yang Xu is an Associate Chief Physician, Associate Professor, and Graduate Supervisor at the Department of Respiratory and Critical Care Medicine, The Eighth Medical Center, Chinese PLA General Hospital. Specializing in the early diagnosis and personalized treatment of lung tumors, Dr. Xu has made significant contributions to respiratory medicine and oncology. As a leading expert in the field, he has played a pivotal role in advancing immune purification and cell therapy, earning widespread recognition for his scientific achievements.

Profile

ORCID

Strengths for the Awards

✅ Expertise in Lung Tumor Diagnosis & Treatment: Yang Xu specializes in the early diagnosis and personalized treatment of lung tumors, which is a crucial area in respiratory and critical care medicine.

✅ Strong Research Contributions: With 6 funded research projects, including National Natural Science Foundation of China and key national R&D plans, his research impact is significant.

✅ Recognition & Patents: Winning 1 medical science and technology progress award and holding 4 national invention patents showcase his innovation and contribution to medical advancements.

✅ Publication Record: Publishing 40 research papers, including 20 SCI-indexed papers, and editing 5 monographs as a deputy principal author indicates a high level of scholarly contribution.

✅ Leadership & Influence: Holding leadership positions in prestigious medical associations such as the Chinese Medical Association and Beijing Medical Association reflects his influence in the field.

🎓 Education

Dr. Xu received his medical education and advanced training in respiratory and critical care medicine, equipping him with the expertise to diagnose and treat complex lung diseases. His academic journey has been marked by rigorous research and continuous professional development in cutting-edge medical technologies.

👨‍⚕️ Experience

With extensive experience in respiratory and critical care medicine, Dr. Xu has led multiple national research projects, including those funded by the National Natural Science Foundation of China and the national key R&D plan. As an esteemed educator and mentor, he has guided numerous students in the field, shaping the next generation of medical professionals. His leadership extends to prestigious roles such as Deputy Leader of the Immune Purification and Cell Therapy Group under the Chinese Medical Association and Deputy Chairman of the Lung Cancer Group in the Respiratory Branch of the Beijing Medical Association.

🔬 Research Interests On Medicine

Dr. Xu’s research focuses on:

  • Lung Tumor Diagnosis & Treatment – Advancing early detection and precision therapy.
  • Immune Checkpoint Inhibitor Pneumonia – Contributing to China’s first expert consensus.
  • Strategic Advanced Electronic Materials – Investigating innovative medical applications.
  • Immune Purification & Cell Therapy – Exploring novel therapeutic strategies in respiratory medicine.

🏆 Awards

Dr. Xu has received numerous accolades for his contributions to medical science, including:

  • Medical Science & Technology Progress Award 🏅
  • 4 National Invention Patents 🏅🏅🏅🏅
  • Excellent Doctor & Excellent Teacher Titles 🏆 (Multiple times)
  • Selected as China’s High-Level Scientific and Technological Innovation Talent 🌟

📚 Publications

  1. Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel flcn Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation
    • Authors: Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang
    • Year: 2025
  2. [Clinical diagnosis and treatment of lung cancer combined with interstitial lung disease]
    • Author: Xu Y
    • Year: 2024
  3. Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer
    • Authors: Yabin Chen, Fang Z, Tang Y, Jin Y, Guo C, Hu L, Xu Y, Ma X, Gao J, Xie M et al.
    • Year: 2021
  4. Clinical characteristics of patients with chronic eosinophilic pneumonia in a Chinese tertiary-care hospital: A 6-year retrospective study
    • Authors: Xu Y, Wang Z, Li W, Zhu Q, Liang Z
    • Year: 2021
  5. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis
    • Authors: Huang A, Xu Y, Zang X, Wu C, Gao J, Sun X, Xie M, Ma X, Deng H, Song J et al.
    • Year: 2021
  6. Perfluorocarbon Protects against Lipopolysaccharide-Induced Apoptosis of Endothelial Cells in Pulmonary Microvessels
    • Authors: Xu Y, Wu T, Wang P, Liang ZX, Shi SS, Xu SF, Liu XJ, Tian Q
    • Year: 2021
  7. Lung cancer treatment in the era of immunotherapy
    • Authors: Xu Y, Liang-an Chen
    • Year: 2020
  8. The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial
    • Authors: Minghui Zhu, Yang Z, Hang Yu, Zhu Q, Xu Y, Li Y, Li C, Zhao W, Zhixin Liang, Liang-an Chen
    • Year: 2020
  9. Identification of differentially expressed genes in hip cartilage with femoral head necrosis, based on genome‑wide expression profiles
    • Authors: Li WC, Bai L, Xu Y, Xu RJ, Hou WB
    • Year: 2019
  10. Cystic and solitary nodular pulmonary metastases in a patient with low-grade endometrial stromal sarcoma: A case report and literature review
  • Authors: Xu Y, Zhixin Liang, Guo JT, Su X, Lu YL, Guan XZ
  • Year: 2019

🔚 Conclusion

Yang Xu is a distinguished leader in respiratory and critical care medicine, driving innovation in lung cancer treatment and immune-related diseases. His contributions to research, education, and clinical practice continue to shape the future of respiratory medicine, making a lasting impact on both national and global healthcare communities.